Skin calming composition

Abstract

Provided are a use of epicatechin or a legume extract containing epicatechin for preparing a composition for tranquilizing skin, and a skin itch treatment method comprising a step of applying a cosmetic composition to the skin of an individual causing itch, the cosmetic composition being the composition for tranquilizing skin.

Description

Technical Field

[0001] The present disclosure relates to a skin-soothing composition and a cosmetic composition containing the same. Background Art

[0002] Sensitive skin reacts more readily to external stimuli than normal skin, resulting in irritation, erythema, and itching. Reports indicate that although sensitive skin has similar moisture content, pH, and melanin content compared to normal skin, it experiences a higher TEWL (transient water evaporation) and secretes more cytokines.

[0003] As described above, although the symptoms that occur in sensitive skin are diverse, the symptoms that occur in sensitive skin are alleviated mainly by replenishing lipids in the stratum corneum of the skin through ceramides to prevent water evaporation.

[0004] On the one hand, examples of sensitive skin include atopic skin or eczema, with typical symptoms of atopic skin and eczema including redness and itching. Itching can occur due to a damaged skin barrier, leading to a loss of moisturizing factors such as filaggrin and ceramide. Itching can also occur due to various external stimuli causing mast cell degranulation, which leads to the release of histamine and the activation of nerve fibers. Therefore, itching can be alleviated by replenishing moisturizing factors to strengthen the skin barrier or by inhibiting mast cell degranulation, thereby suppressing histamine release and nerve fiber activation. Traditionally, itching has been alleviated by replenishing moisturizing factors to strengthen the skin barrier. Summary of the Invention

[0005] Technical problems to be solved

[0006] One embodiment provides a composition capable of inhibiting mast cell degranulation and increasing the expression of claudin-1 protein.

[0007] Another embodiment provides a cosmetic composition that can relieve skin itching, strengthen the skin barrier, and thus calm the skin.

[0008] Solution to the problem

[0009] According to one embodiment, a skin soothing composition is provided, comprising epicatechin or a bean extract containing epicatechin as an active ingredient.

[0010] The bean extract may be an extract of a new variety of beans with the accession number KCTC14220BP.

[0011] The bean extract may contain 2 to 7 wt % of epicatechin based on the total weight of 80 wt % of the ethanol aqueous solution extract of the new variety of beans.

[0012] The composition may contain 1 ppm to 5000 ppm of the epicatechin or the bean extract containing the epicatechin, based on the total weight of the composition.

[0013] The skin soothing may be skin soothing by alleviating or suppressing itching.

[0014] The skin soothing may be skin soothing by improving the skin barrier.

[0015] The skin soothing may be skin soothing by retaining skin moisture.

[0016] The skin soothing may be skin soothing by suppressing redness.

[0017] The skin soothing may be achieved by improving skin adhesion.

[0018] The skin soothing may be skin soothing by improving skin allergies.

[0019] According to another embodiment, a cosmetic composition is provided, which includes the skin-calming composition.

[0020] The cosmetic composition may contain 0.1 wt % to 10 wt % of the skin soothing composition based on the total weight of the cosmetic composition.

[0021] The cosmetic composition may be a cosmetic composition for alleviating itching.

[0022] It may be characterized in that the pruritus relief inhibits the degranulation of mast cells, thereby relieving pruritus.

[0023] According to another embodiment, a use of epicatechin or a bean extract containing epicatechin for preparing a skin-soothing composition is provided.

[0024] The use may be that the bean extract is an extract of a new variety of beans with a preservation number of KCTC14220BP.

[0025] The bean extract may contain 2 to 7 weight percent of epicatechin based on the total weight of 80 weight percent of the ethanol aqueous solution extract of the new variety of beans.

[0026] The use may be to contain 1 ppm to 5000 ppm of the epicatechin or the bean extract containing the epicatechin, based on the total weight of the composition.

[0027] The use may be that the skin soothing is skin soothing by relieving or suppressing itching, skin soothing by improving the skin barrier, skin soothing by retaining skin moisture, skin soothing by suppressing flushing, skin soothing by improving skin adhesion, or skin soothing by improving skin allergies.

[0028] The skin calming composition may be used as a cosmetic composition.

[0029] The application may be that the cosmetic composition contains 0.1 wt % to 10 wt % of the skin soothing composition based on the total weight of the cosmetic composition.

[0030] The cosmetic composition may be used for alleviating itching.

[0031] The use may be that the relieving of itching is to inhibit the degranulation of mast cells, thereby relieving the itching.

[0032] According to another embodiment, a method for treating skin itching is provided, comprising: applying the cosmetic composition to the skin of an individual causing itching.

[0033] Effects of the Invention

[0034] The composition according to one embodiment can inhibit the degranulation of mast cells and increase the expression of claudin-1 protein. Therefore, the cosmetic composition according to another embodiment comprising the composition can relieve skin itching and strengthen the skin barrier. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 This is a graph showing the evaluation results of the inhibition of mast cell degranulation induction;

[0036] Figure 2 This is a photo of artificial skin showing the results of the skin adhesion evaluation;

[0037] Figure 3 This is a photo of artificial skin showing the results of moisturizing factor evaluation;

[0038] Figure 4 This is a graph showing the results of skin flushing evaluation. DETAILED DESCRIPTION

[0039] Hereinafter, an implementation example of the present invention will be described in detail so that a person having ordinary knowledge in the technical field to which the present invention belongs can easily implement it. However, the present invention can be implemented in various forms and is not limited to the implementation example described here.

[0040] In the present specification, the "active ingredient" refers to an ingredient that can exhibit the desired activity alone or an ingredient that can exhibit activity together with a carrier that is inactive by itself.

[0041] One embodiment provides a skin soothing composition comprising epicatechin or a bean extract containing epicatechin as an active ingredient.

[0042] Mast cells, immune cells that are the primary cause of allergies, have surface factors on their surfaces that bind to IgE antibodies. When IgE antibodies bind to their surface, mast cells become activated. Activated mast cells degranulate neurotransmitters such as histamine, resynthesizing and secreting lipid mediators like cytokines, prostaglandins, and leukotrienes, leading to itching symptoms. Furthermore, the inflammatory factors secreted during mast cell degranulation weaken the intercellular bonds in the granular layer, weakening the skin's adhesion and making it more susceptible to damage from external stimuli.

[0043] The inventors of this application have confirmed that a composition containing epicatechin or a bean extract containing epicatechin according to one embodiment inhibits mast cell degranulation, thereby suppressing histamine release and nerve fiber activation, thereby calming the skin by relieving pruritus and other symptoms. The inventors have also confirmed that the composition exhibits similar effects to ketotifen, a conventional pruritus suppressant. Furthermore, the inventors have confirmed that the composition, by inhibiting mast cell degranulation, improves the skin barrier, retains skin moisture, suppresses skin redness, improves skin adhesion, and alleviates skin allergies, ultimately achieving skin soothing effects.

[0044] The pruritus-relieving effect mentioned here refers to the pruritus-relieving effect achieved by inhibiting mast cell degranulation, rather than by relieving pruritus through an anti-inflammatory effect. Generally, anti-inflammatory effects refer to effects that prevent or ameliorate inflammation, meaning the prevention or amelioration of inflammation in tissues of an individual, including the skin. Such inflammation includes inflammation caused by external stressors such as ultraviolet light or oxidants in tissues including the skin, which can be skin tissue or non-skin tissue, such as lung tissue. Such inflammation itself can constitute a disease, such as atopic dermatitis or chronic obstructive pulmonary disease (COPD). However, the composition according to one embodiment has no anti-inflammatory effect related to the prevention or amelioration of such inflammation. In other words, unlike managing inflammation caused by external stressors, the composition, in the case of dry skin with an inherently fragile skin barrier, often experiences flushing, tightness, and itching regardless of external stress, by inhibiting mast cell degranulation, thereby alleviating or calming such itching. In this respect, the composition according to one embodiment is completely different from conventional anti-pruritus compositions that rely on anti-inflammatory responses. Furthermore, conventional anti-pruritic compositions based on anti-inflammatory (or anti-aging or antioxidant) effects have nothing to do with inhibiting mast cell degranulation, and their structures and mechanisms are fundamentally different. (Previous anti-pruritic compositions mostly alleviate pruritus by maximizing anti-inflammatory effects through inhibition of genes such as PGE2, PLA2, COX-2, IL-2, IL-3, IL-4, IL-13, and TSLP.) Furthermore, ketotifen, a ketone used as a pruritus treatment, selectively inhibits degranulation, thereby suppressing histamine release. This inhibition of histamine release in response to external or internal stimulation can reduce pruritus.

[0045] Furthermore, it was confirmed that the composition containing epicatechin or a bean extract containing epicatechin can increase the expression of claudin-1 protein involved in tight junctions, strengthen skin with weakened cell adhesion, relieve itching, and calm the skin.

[0046] The epicatechin contained in the composition may be represented by the following Chemical Formula 1, but is not limited thereto.

[0047]

Chemical Formula 1

[0048]

[0049] The bean extract can be obtained by extracting a new variety of beans with a preservation number of KCTC14220BP. The new variety of beans can be obtained by hybridizing IT109098 (broad-leaved creeping bean) as the female parent and the semi-wild species K7-2 as the male parent.

[0050] The new variety of bean extract may contain 2 weight % or more, 2.1 weight % or more, 2.2 weight % or more, 2.3 weight % or more, 2.4 weight % or more, 2.5 weight % or more, 2.6 weight % or more, 2.7 weight % or more, 2.8 weight % or more, 2.9 weight % or more, 3 weight % or more, 3.1 weight % or more, 3.2 weight % or more, 3.3 weight % or more, 3.4 weight % or more, 3.5 weight % or more, 3.6 weight % or more, 3.7 weight % or more, 3.8 weight % or more, 3.9 weight % or more, 4 weight % or more, 4.1 weight % or more, or 4.2 weight % or more of epicatechin, based on the total weight of the extract obtained by extracting the new variety of beans using 80% ethanol aqueous solution. Furthermore, epicatechin may be contained in an amount of 7% by weight or less, 6.8% by weight or less, 6.6% by weight or less, 6.4% by weight or less, 6.2% by weight or less, 6% by weight or less, 5.8% by weight or less, 5.6% by weight or less, or 5.4% by weight or less. The bean extract contains epicatechin in the above-described range, and the composition containing the bean extract can fully exhibit the pruritus-relieving effect.

[0051] The skin soothing composition may contain 1 ppm to 1000 ppm of epicatechin or a bean extract containing epicatechin, based on the total weight of the composition. The composition may contain, for example, 1 ppm to 900 ppm, for example, 1 ppm to 800 ppm, for example, 1 ppm to 700 ppm, for example, 1 ppm to 600 ppm, for example, 1 ppm to 500 ppm, for example, 2 ppm to 1000 ppm, for example, 3 ppm to 1000 ppm, for example, 4 ppm to 1000 ppm, for example, 5 ppm to 1000 ppm, for example, 10 ppm to 1000 ppm, for example, 10 ppm to 500 ppm of epicatechin or a bean extract containing epicatechin, without limitation. The composition contains epicatechin or a bean extract containing epicatechin in this range, and thus the composition containing the same can fully exert the effect of alleviating pruritus.

[0052] The skin-soothing composition can soothe the skin in multiple ways. For example, it can soothe the skin by relieving or suppressing itching symptoms, and can also soothe the skin by retaining moisture. Furthermore, it can soothe the skin by suppressing flushing, improving skin cell adhesion or the skin barrier, or allergic reactions.

[0053] Another embodiment provides a cosmetic composition comprising the aforementioned composition for inhibiting mast cell degranulation.

[0054] The cosmetic composition may contain 0.1% to 10% by weight of the composition for inhibiting mast cell degranulation, based on the total weight, and may contain, for example, 0.1% to 10% by weight, for example, 0.1% to 9% by weight, for example, 0.1% to 8% by weight, for example, 0.1% to 7% by weight, for example, 0.1% to 6% by weight, for example, 0.1% to 5% by weight, for example, 0.2% to 10% by weight, for example, 0.3% to 10% by weight, for example, 0.4% to 10% by weight, for example, 0.5% to 10% by weight, for example, 0.6% to 10% by weight, for example, 0.7% to 10% by weight, for example, 0.8% to 10% by weight, for example, 0.9% to 10% by weight, for example, 1.0% to 10% by weight, and is not limited thereto. The cosmetic composition contains the composition for inhibiting mast cell degranulation in the above content range, so that the cosmetic composition can be used on the skin without other side effects and can fully exert the itching relief effect.

[0055] The cosmetic composition can relieve itchy skin. Itchy skin can be caused by a dry external environment and loss of moisturizing factors, or it can be caused by mast cell degranulation. When applied to the skin, the cosmetic composition not only inhibits mast cell degranulation, thereby inhibiting histamine release and nerve fiber activation, thus alleviating itchy skin, but also suppresses skin flushing and the occurrence of skin allergies, thereby calming the skin. Furthermore, the cosmetic composition can strengthen the cell adhesion (tight junctions) within the epidermal granular layer of the skin, thereby strengthening cell cohesion, improving the skin barrier, and alleviating itchy skin. Furthermore, by strengthening skin cell cohesion, the cosmetic composition can inhibit the loss of moisturizing factors, maintain skin moisture, alleviate pruritus, and provide a calming effect. The cosmetic composition is primarily applied to the skin, and therefore, similar to cosmetic compositions known in the art, can also be formulated into any conventionally manufactured dosage form. For example, the formulation may be in the form of a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, a surfactant-containing cleanser, an oil, a powder-type liquid foundation, an emulsion-type liquid foundation, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, microneedles, foam, aerosol, wax-type liquid foundation, and spray, but is not limited thereto.

[0056] The cosmetic composition can have dosage forms such as skin softening lotion, astringent lotion, nourishing lotion, nourishing cream, massage cream, eye cream, eye essence, essence, cleansing cream, cleansing milk, cleansing foam, makeup remover, facial mask, powder, body lotion, body cream, body essence, body cleanser, hair dye, shampoo, conditioner, hair styling agent, hair nourishing agent, ointment, gel, cream, patch, spray, powder and skin adhesive type, but is not limited thereto.

[0057] In the dosage form, in addition to the essential components, those skilled in the art can easily select and prepare other components appropriately according to the type or purpose of other external preparations.

[0058] When the cosmetic composition is in the form of a paste, cream or gel, it may contain animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivatives, polyethylene glycol, silicon, bentonite, silicon dioxide, talc or zinc oxide as a carrier component.

[0059] When the cosmetic composition is in the form of a powder or spray, it may contain lactose, talc, silicon dioxide, aluminum hydroxide, calcium silicate or polyamide powder as a carrier component. In particular, when it is a spray, it may further contain a propellant such as chlorofluorocarbons, propane / butane, dimethyl ether, etc.

[0060] When the dosage form of the cosmetic composition is a solution or an emulsion, it may contain a solvent, a solvating agent, an emulsifier, etc. as a carrier component, specifically, it may contain water, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol oil, glycerol fatty acid ester, polyethylene glycol, fatty acid ester of sorbitan, etc.

[0061] When the dosage form of the cosmetic composition is a suspension, it can contain liquid diluents such as water, ethanol, propylene glycol, etc.; suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitan ester, polyoxyethylene sorbitan ester, etc.; microcrystalline cellulose; aluminum metahydroxide; bentonite; agar; tragacanth gum, etc. as carrier components.

[0062] When the cosmetic composition is in the form of a surfactant-containing cleanser, it may contain fatty alcohol sulfates, fatty alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazoline derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulfates, alkylamide betaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, ethoxylated glyceryl fatty acid esters, etc. as carrier components.

[0063] On the one hand, another embodiment provides a method for treating skin itching, comprising: applying the cosmetic composition to the skin of an individual causing itching.

[0064] Regarding the step of applying the cosmetic composition to the skin of the individual causing the itch, any form of application, injection, etc. can be used without limitation, as long as the cosmetic composition can exert its effect. In addition, the method for treating skin itch refers to a method for alleviating, suppressing, reducing, or reducing skin itch symptoms.

[0065] Hereinafter, the implementation examples of the present invention will be described in more detail through examples. However, the following examples are only for illustrative purposes and do not limit the scope of the present invention.

[0066] Preparation of bean extracts

[0067] Preparation Example

[0068] The new soybean variety, with accession number KCTC14220BP, was pulverized using a grinder (Tube Mill 100 Control, IKA) to produce a powder. 100 g of the resulting bean powder was added to 1 L of 80% ethanol aqueous solution and extracted at room temperature (25°C) for 24 hours. The extract was then filtered through filter paper. The filtered extract was then dried using a vacuum concentrator to yield 15.7 g of extract.

[0069] Preparation of composition

[0070] Example 1

[0071] A skin soothing composition was prepared by adding 1 g of epicatechin (EC, CAS NO. 490-46-0) to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock solution, which was then diluted to 1 ppm using a culture medium.

[0072] Example 2

[0073] A skin soothing composition was prepared by adding 1 g of epicatechin (EC, CAS No. 490-46-0) to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock solution, which was then diluted with culture medium to a concentration of 10 ppm.

[0074] Example 3

[0075] A skin soothing composition was prepared by adding 1 g of epicatechin (EC, CAS NO. 490-46-0) to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock solution, which was then diluted to 50 ppm using a culture medium.

[0076] Example 4

[0077] 1 g of the bean extract obtained in the above preparation example was added to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock solution, which was then diluted to 1 ppm using a culture medium to prepare a skin soothing composition.

[0078] Example 5

[0079] 1 g of the bean extract obtained in the above preparation example was added to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock solution, which was then diluted to 10 ppm using a culture medium to prepare a skin soothing composition.

[0080] Example 6

[0081] 1 g of the bean extract obtained in the above preparation example was added to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock solution, which was then diluted to 50 ppm using a culture medium to prepare a skin soothing composition.

[0082] Example 7

[0083] 1 g of the bean extract obtained in the above preparation example was added to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock solution, which was then diluted to 100 ppm using a culture medium to prepare a skin soothing composition.

[0084] Comparative Example 1

[0085] Purified water or dimethyl sulfoxide (DMSO) was used.

[0086] Comparative Example 2

[0087] 1 g of palmitoylethanolamide (PEA) was added to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock solution, which was then diluted with culture medium to a concentration of 1 ppm to prepare a composition.

[0088] Comparative Example 3

[0089] 1 g of palmitoylethanolamide (PEA) was added to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock solution, which was then diluted with culture medium to a concentration of 10 ppm to prepare a composition.

[0090] Comparative Example 4

[0091] A stock solution of 1g of palmitoylethanolamide (PEA) was prepared by adding it to 100g of purified water or dimethyl sulfoxide (DMSO). This solution was then diluted to 50ppm using culture medium to prepare the composition. Since PEA becomes suspended at 50ppm, it was not used in the experiment.

[0092] Comparative Example 5

[0093] A composition was prepared by adding 1 g of (-)-epigallocatechin gallate (EGCG) to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock solution, which was then diluted to 1 ppm using culture medium.

[0094] Comparative Example 6

[0095] A composition was prepared by adding 1 g of (-)-epigallocatechin gallate (EGCG) to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock solution, which was then diluted to 10 ppm using culture medium.

[0096] Comparative Example 7

[0097] A stock solution of (-)-epigallocatechin gallate (EGCG) (1g) was added to 100g of purified water or dimethyl sulfoxide (DMSO). This solution was then diluted to 50ppm using culture medium to prepare the composition. Due to its cytotoxicity, 50ppm of EGCG was not used in the experiment.

[0098] The ingredients and concentrations of the compositions of Examples 1 to 6 and Comparative Examples 1 to 7 are summarized in Table 1 below.

[0099]

Table 1

[0100]

[0101] Evaluation 1: Evaluation of inhibition of degranulation induction

[0102] 1) Culture of RBL-2H3 cell line

[0103] RBL-2H3 cell line (basophil leukemia cell line) was purchased from the Korean Cell Line Bank (22256) and cultured in a CO2 incubator at 37°C under 5% CO2. DMEM media (with 10% FBS and 1% antibiotics) was used as the culture medium.

[0104] 2) Treat RBL-2H3 cells with substances

[0105] 4 × 10 4 After splitting the RBL-2H3 cells at the same number of cells / well, the cells were cultured in a 37°C, 5% CO2 incubator until confluence reached approximately 80%. After one day of treatment with the allergen DNP-IgE (200 ng / ml), the mast cells were activated twice with DNP-BSA (1 ug / ml) and simultaneously treated with the compositions of Examples 1 to 6 and Comparative Examples 1, 2, 3, 5, and 6.

[0106] 3) Determination of mast cell degranulation (β-hexosaminidase assay)

[0107] After incubating the cells treated with the substance in step 2) in an incubator for 1 hour, transfer 50 μl of sup from each well to a new 96-well plate. Add 50 μl of substrate solution and incubate in an incubator for 1 hour. Add 100 μl of stop solution, confirm yellowing, and measure absorbance at 405 nm. Triton-X100 is used as the positive substance. Figure 1 The results are shown in .

[0108] refer to Figure 1It was confirmed that the compositions of Examples 1 to 6 significantly inhibited mast cell degranulation compared to the compositions of Comparative Examples 1, 2, 3, 5, and 6, which treated DNP-IgE and DNP-BSA. Specifically, it was confirmed that treatment with a composition containing epicatechin or a bean extract containing epicatechin inhibited the induction of mast cell degranulation by an allergen. Therefore, it was confirmed that a cosmetic composition containing such a composition can simultaneously alleviate or suppress skin itching and exert an inhibitory effect on skin allergies caused by mast cell degranulation.

[0109] Evaluation 2: Evaluation of skin adhesion and moisturizing factor

[0110] After artificial skin was treated with an inflammatory cocktail (IFN-r (20 ng / ml) + TNF-α (20 ng / ml)) and the compositions according to Comparative Examples 1, 4, 7, Examples 3, and 6, the expression levels of the skin-binding factor claudin-1 protein and the moisturizing factor filaggrin protein were compared. The results were as follows: Figure 2 and Figure 3 shown.

[0111] refer to Figure 2 It was confirmed that when the artificial skin was treated with only the inflammatory cocktail, claudin-1 protein expression decreased, weakening cell-cell bonding and blurring the boundaries between cell layers. In the artificial skin treated with the compositions according to Comparative Examples 1, 4, and 7, it was confirmed that the reduced claudin-1 protein expression was not restored, resulting in unclear boundaries between cell layers. In contrast, in the artificial skin treated with the compositions according to Examples 3 and 6, the reduced claudin-1 protein expression was restored, resulting in clearer boundaries between cell layers. In other words, it was confirmed that the compositions according to the Examples containing epicatechin or a bean extract containing epicatechin were effective in increasing claudin-1 protein expression.

[0112] refer to Figure 3It was confirmed that when the artificial skin was treated with only the inflammatory cocktail, expression of the moisturizing factor filaggrin protein decreased, blurring the boundaries between cell layers. In the artificial skin treated with the compositions according to Comparative Examples 1, 4, and 7, it was confirmed that the reduced filaggrin protein expression was not restored, resulting in unclear boundaries between cell layers. In contrast, in the artificial skin treated with the compositions according to Examples 3 and 6, the reduced filaggrin protein expression was restored, resulting in clearer boundaries between cell layers. In other words, it was confirmed that the compositions according to the Examples containing epicatechin or a bean extract containing epicatechin were effective in increasing filaggrin protein expression.

[0113] On the one hand, reference Figure 2 and Figure 3 It was confirmed that palmitoylethanolamide (PEA), which is known to have a skin inflammation inhibitory effect rather than a mast cell degranulation inhibitory effect, did not restore the reduced claudin-1 and filaggrin protein expressions when treated with the composition according to Comparative Example 4 containing PEA.

[0114] Evaluations 2 and 3 confirmed that the composition containing epicatechin or a bean extract containing epicatechin reduces water loss from the skin, improves the skin's moisturizing capacity, and strengthens the skin barrier by strengthening the tight junctions between cells in the granular layer of the skin.

[0115] Evaluation 3: Evaluation of skin flushing

[0116] Artificial skin was treated with inflammatory factors (TNF-α + IFN-r (20 ng / ml)) and the compositions of Examples 2, 3, 5, 6, and 7 and Comparative Examples 3, 4, 6, and 7, and the amount of PGE2 (prostaglandin E2) was measured. PGE2 is a factor that induces vasodilation, which causes skin flushing. The lower the amount of PGE2, the less vasodilation is induced, which can be interpreted as suppressing skin flushing. The results of the skin flushing evaluation were: Figure 4 shown.

[0117] refer to Figure 4 It was confirmed that the amount of PGE2 was suppressed when the compositions according to Examples 3, 6, and 7 were used. Thus, it was confirmed that the composition containing epicatechin or a bean extract containing epicatechin can suppress the redness of the skin.

[0118] The preferred embodiments of the present invention are described in detail above. However, the scope of the present invention is not limited thereto. Various modifications and improvements made by those skilled in the art using the basic concepts of the present invention defined in the appended claims also fall within the scope of the present invention.

[0119]

Accession number

[0120] Korea Biotechnology Research Institute, KCTC14220BP, 20200619

Claims

1. Use of epicatechin or a bean extract containing epicatechin for preparing a skin-soothing composition.

2. The use according to claim 1, wherein: The bean extract is an extract of a new variety of beans with a preservation number of KCTC14220BP.

3. The use according to claim 2, wherein: The bean extract contains 2 to 7 weight percent of epicatechin based on the total weight of 80 weight percent of the ethanol aqueous solution extract of the new variety of beans.

4. The use according to claim 1, wherein: The composition contains 1 ppm to 5000 ppm of the epicatechin or the bean extract containing the epicatechin, based on the total weight of the composition.

5. The use according to claim 1, wherein: The skin soothing is skin soothing by relieving or suppressing itching, skin soothing by improving the skin barrier, skin soothing by retaining skin moisture, skin soothing by suppressing flushing, skin soothing by improving skin adhesion, or skin soothing by improving skin allergies.

6. The use according to claim 1, wherein: The skin calming composition is a cosmetic composition.

7. The use according to claim 6, wherein: The cosmetic composition contains 0.1 wt % to 10 wt % of the skin soothing composition based on the total weight of the cosmetic composition.

8. The use according to claim 6, wherein: The cosmetic composition is a cosmetic composition for relieving itching.

9. The use according to claim 8, wherein: The relieving of pruritus is to inhibit the degranulation of mast cells, thereby relieving the pruritus.

10. A method for treating skin itching, comprising: A step of applying the cosmetic composition according to claim 6 to the skin of an individual causing itching.

Images